## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Medical technologies evaluation programme

### **Equality impact assessment: Guidance development**

# MT330 Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

#### Medical technology consultation document 1

Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
N/A
2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?
N/A
3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?
No equality issues were identified during guidance development. People likely to

benefit from this technology may have disabilities causing issues with mobility. They may be considered to be disabled if their condition has a substantial and long-term negative effect on the ability to do normal daily activities. Disability is a protected

characteristic under the Act. However, there are no special considerations

Equality impact assessment: MT311 (guidance development)

specifically related to equality issues.

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?						
No	No						
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?						
No	No						
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?						
N/	N/A						
7.	Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?						
N/	A						

Approved by Associate Director: Mark Campbell

Date: 31 October 2017

### Medical technology consultation document 2

**1.** Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Yes. Some consultees were concerned the draft recommendations excluded the use of Senza spinal cord stimulation system for delivering HF10 therapy in patients who had not had previous back surgery. The committee address this by amending section 1.2.

2.	If the recommendations have changed after consultation, are there any
	recommendations that make it more difficult in practice for a specific
	group to access the technology compared with other groups? If so, what
	are the barriers to access for the specific group?

No.

**3.** If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

**5.** Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

N/A		

**Approved by Acting Programme Director:** Mark Campbell

Date: 13 September 2018

### Medical technology guidance document

**6.** Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Yes. Some consultees were concerned the draft recommendations excluded the use of Senza spinal cord stimulation system for delivering HF10 therapy in patients who had not had previous back surgery. The committee address this by amending section 1.2.

7. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The committee became aware of the need to help promote equality of access and understood that some people may have difficulties responding to tests to assess pain especially if visual analogue scales are used as described in 1.2. It agreed to add a recommendation making clear that multi-disciplinary teams should consider this in the new 1.5.

**8.** If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

9. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A	

**10.**Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

Yes in section 1.5

Approved by Acting Programme Director: Mark Campbell

Date: 30 October 2018